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Abstract
Stress is a complex human experience and having both rewarding and aversive motivational properties. The adverse effects
of stress are well documented, yet many of underlying mechanisms remain unclear and controversial. Here we report that
the anxiogenic properties of stress are encoded by the endogenous opioid peptide dynorphin acting in the basolateral
amygdala. Using pharmacological and genetic approaches, we found that the anxiogenic-like effects of Corticotropin
Releasing Factor (CRF) were triggered by CRF1-R activation of the dynorphin/kappa opioid receptor (KOR) system. Central
CRF administration significantly reduced the percent open-arm time in the elevated plus maze (EPM). The reduction in
open-arm time was blocked by pretreatment with the KOR antagonist norbinaltorphimine (norBNI), and was not evident in
mice lacking the endogenous KOR ligand dynorphin. The CRF1-R agonist stressin 1 also significantly reduced open-arm time
in the EPM, and this decrease was blocked by norBNI. In contrast, the selective CRF2-R agonist urocortin III did not affect
open arm time, and mice lacking CRF2-R still showed an increase in anxiety-like behavior in response to CRF injection.
However, CRF2-R knockout animals did not develop CRF conditioned place aversion, suggesting that CRF1-R activation may
mediate anxiety and CRF2-R may encode aversion. Using a phosphoselective antibody (KORp) to identify sites of dynorphin
action, we found that CRF increased KORp-immunoreactivity in the basolateral amygdala (BLA) of wildtype, but not in mice
pretreated with the selective CRF1-R antagonist, antalarmin. Consistent with the concept that acute stress or CRF injection-
induced anxiety was mediated by dynorphin release in the BLA, local injection of norBNI blocked the stress or CRF-induced
increase in anxiety-like behavior; whereas norBNI injection in a nearby thalamic nucleus did not. The intersection of stress-
induced CRF and the dynorphin/KOR system in the BLA was surprising, and these results suggest that CRF and dynorphin/
KOR systems may coordinate stress-induced anxiety behaviors and aversive behaviors via different mechanisms.
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Introduction
Stress is a complex human experience and has both rewarding as
well as aversive motivational properties. The adverse effects of stress
are well documented, yet many of the underlying mechanisms
remain unclear and controversial. Stress mobilizes the corticotropin
releasing factor (CRF)/urocortin neuropeptide systems to activate
the hypothalamic-pituitary- adrenal axis (HPA), and extra-hypo-
thalamic actions of CRF can stimulate the neuronal circuits
responsible for stress-induced anxiety, dysphoria, and reinstatement
of drug abuse behaviors [1–8]. In rodent models of motivated
behavior, CRF produces conditioned place aversion (CPA) [1,7],
and in some cases CRF receptor antagonists have antidepressant
effects in human studies [9]. Other groups have demonstrated that
CRFhas anxiogenicproperties [10–12],andithasbeenposited that
these effects of CRF initiate stress-induced relapse to drug seeking
and drug withdrawal behaviors [3,4,6,13,14].
CRF acts directly on neurons in key regions of the central
nervous system (e.g. bed nucleus of the stria terminalis and
amygdalar complex) to coordinate the behavioral stress response
through the activation of two receptor subtypes [15]. The CRF
system is comprised of the neuropeptides CRF and urocortin I that
bind to and activate both CRF1-receptors (CRF1-R) and CRF2-
receptors; whereas the peptides urocortin II and urocortin III are
more selective CRF2-receptor agonists [15,16]. CRF1-R activity is
thought to be prodepressant and anxiogenic [10,11,15], whereas
CRF2-R activity has been suggested to have a complementary
stress coping role. However, the processes by which CRF and the
urocortins mediate stress-induced behaviors through their two
receptor systems are still under active investigation.
Recent work has shown that the aversive effects of stress can be
mediated by CRF-induced activation of type 2 CRF receptors
(CRF2-R) and subsequent activation of kappa opioid receptors
(KOR) by dynorphin [1]. The dynorphin/KOR system is a
critical mediator in stress-induced depression and stress-induced
reinstatement of drug-seeking [8,17–21]. These previous studies
provided new insight into a potential connection between the
dynorphin/KOR and stress-CRF systems. It also suggested that
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by an initial anxiety-like response during the CRF or stress
experience. Interestingly, a possible role for stress-induced
dynorphin release in anxiety-like behavior has been suggested
[22], but a relationship to CRF has not been established. In this
study, we dissected the linkage between the CRF and dynorphin
systems in the brain, and studied how these interactions may
mediate anxiety-like behaviors.
Materials and Methods
Animals
Male C57Bl/6 mice (Charles River) weighing 22–30 g were
used. Prodynorphin (Pdyn) gene deletion on C57Bl/6 background
were generated as previously described [1]. CRF2-R(2/2) and
CRF1-R(2/2) mice were gifts of Antonello Bonci and Wylie
Vale, and were backcrossed to a C57Bl/6 background for $5
generations in our laboratory (in addition to ,5 generations in the
previous laboratory). Pair-wise knockout and littermate control
wild type mice were used throughout the experimental studies
described. We also note that the viability of CRF1-R(2/2) mice
on C57Bl/6 background was very poor; heterozygote crosses
produced significantly fewer homozygous CRF1-R (2/2) male
mice than predicted (p,0.05, chi square, data not shown). After 1
year of breeding, only 2 of these mice survived stereotaxic surgery
and were used, and only for qualitative anatomical analysis. All
animal protocols were approved by the UW Institutional Animal
Care and Use Committee.
Drugs and Chemicals
Rat/human corticotropin releasing factor (CRF), norbinaltorphi-
mine (norBNI)-HCl, cyclo (31–34)[D-Phe
12,Nle
21,38,Glu
31,L y s
34]Ac-
hCRF (4–41) (stressin 1), and (6)U50,488 were from Tocris
Bioscience (Ellisville, MO). Additional U50,488 and norBNI were
provided by the NIDA Drug supply program. Mouse urocortin III
was from Phoenix Pharmaceuticals (Belmont, CA). Peptides were
dissolved in saline/0.05% acetic acid. U50,488 and norBNI were
dissolved in saline. Drugs were administered at 10 ml/kg (i.p.) or
2 ml/animal (i.c.v).
Intracerebroventricular (i.c.v.) Cannulation and Local
norBNI Injections
Mice were cannulated and injected i.c.v. as previously described
[1]. Following surgery mice recovered for 6–8 days. Mice were
slowly injected (2 min) with saline or peptide (CRF, urocortin III,
or stressin I, 2 ml, i.c.v.), then either placed in the testing chamber
for place aversion studies or back in their home cage in the
darkened elevated plus maze testing room for 30 min prior to
EPM testing. One week prior to i.c.v. injection of peptide, some
mice were also anesthetized and injected bilaterally in the BLA
(lateral 63.1 mm, posterior 21.8 mm, and 5 mm depth (from
bregma) or VPN (ventral posterior thalamic nucleus) (lateral
61.37, posterior 21.82, and 4.35 depth) with norBNI or vehicle at
100 nl/min (10 min), using a Hamilton syringe (1 ml, 12.5u beveled
tip) adapted from Shirayama et al [23]. The needle was removed
3–5 min after injection. Because norBNI is a long-lasting
antagonist and blocks KOR for up to 3 weeks in vivo [24,25], we
were able to wait 1 week after the injection to allow animals to
recover from injection and surgery prior to EPM testing. After
behavioral testing, sites of local norBNI injection and receptor
blockade were confirmed by measuring KORp-ir induced by 10
mg/kg U50,488 given 30 min prior to perfusion. We did not
observe any lesions or gliosis at any of the injection sites, and the
needle track was no longer visible 2 weeks after injection. We also
note that due to low birth rate (see above), and low survival rate of
CRF1-R (2/2) male mice (20%) following i.c.v. cannulation
surgery (24 hrs to 1 week), as compared to .95% surgery survival
for all other wild type and knockout groups, we were unable to
generate sufficient age-matched controls to successfully use this
group in our behavioral studies.
Elevated Plus Maze (EPM) Testing
EPM testing was performed in a sound attenuated room with
dark brown walls and black ceiling, maintained at 23uC. For all
studies (except supplemental figure 1, which was performed at
200 lux), lighting was 50 lux, and performed in the afternoon
between 13:00–1600 hrs. This procedure is widely accepted to
have predictive validity based on responses to anxiolytic drugs
[26,27]. The EPM (Med Associates, St Albans, VT) was made of
black plastic (dimensions: 38 cm Open Arm length67.62 cm
Width674 cm Height, with a 0.5 cm lip on each open arm) and
was cleaned with 70% ethanol between trials. For testing, mice
were placed in the center sector of the maze facing the open arm
and allowed to roam freely for 6 min. Movements were video-
recorded and analyzed using Ethovision (Noldus, Netherlands).
We used open or closed arm times expressed as percentages total
time as our primary measures of anxiety-like behaviors. The
observed locomotor activity in the EPM was not different between
groups, because total arm entry estimates (2166) were not
statistically different between groups, suggesting that mice freely
roamed the maze. Furthermore, all drug treatments/injections
occurred 30 min prior to placing animals in the maze, a time that
is well after the peak hypolocomotor effects of KOR agonism.
Acute stress-induced EPM behavior following local drug or
vehicle injection into BLA, was measured following a modified
acute swim stress exposure [28]. Mice were placed for 5 min in a 5
L beaker (40 cm tall625 cm in diameter) filled with 3.5 L of 30uC
water, carefully dried after removal, and then placed back in the
home cage for 30 min in order to mimic the time between i.c.v.
CRF injection and testing described above. Mice were then tested
for time spent in the open and closed arms of the EPM.
Conditioned Place Aversion
Cannulated mice were trained in a balanced, three-compart-
ment conditioning apparatus as described [1]. Lack of compart-
ment bias was confirmed in this study by the experimental results
(described below). Briefly, mice were pretested in the apparatus,
and time spent in each compartment during the 30 min session
was video recorded and analyzed using Ethovision (Noldus). Mice
were randomly assigned drug and saline training compartments in
a counterbalanced experimental design, and received saline (2 mL,
i.c.v.) in the mornings and CRF (1 mg/2 mL i.c.v.) in the
afternoons of days 2 and 3. Aversion was assessed on day 4 by
recording time spent in each of the 3 compartments during a 30
min post-training session. Preference or aversion scores are
presented as the time each individual animal spent in the drug
paired side in the post-test minus the time spent in the drug-paired
side during the pre-test.
Immunohistochemistry
Procedures to assess KORp-ir were previously described [1,29].
Cannulated mice were i.c.v. injected with CRF or saline, then 30
min later were anesthetized with isoflurane (Sigma) and intracar-
dially perfused with 4% paraformaldehyde in phosphate buffer
(PB) (0.1 M sodium phosphate, pH 7.4). For those animals that
had been locally injected with norBNI, mice were injected with
U50,488 (10 mg/kg, i.p.) 30 min prior to cardio-perfusion. Brains
were dissected and cryoprotected with solution of 30% (w/v)
Dynorphin and Anxiety
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placed in PB until processing. Affinity purified rabbit anti-
phospho-KOR (KORp) antibody (1:50 dilution) [30] diluted in
blocking buffer: PBS containing 0.3% triton X-100 and 5%
normal goat or donkey sera, was used at 15–30 mg/section.
Sections were subsequently washed with PBS then incubated with
anti-Rabbit IgG Alexa Fluor 488, 555 or 633 (1:500, Molecular
Probes, Eugene, OR). Positive KORp-immunoreactive (ir) cells
were quantified from 2–4 separate BLA slices taken from 2–4
animals (fields of 600 mm
2) that were assigned letters and counted
by investigators blind to treatment group. A cell designated as
positive for KORp-ir if optical density was above a standardized
background threshold value for each treatment group, as
determined by using Metamorph software (Dovingtown, PA).
Data Analysis
Data are expressed as means +/2 SEM. For experiments
having a 262 design, two-way ANOVAs were used, followed by
Bonferroni post-hoc tests if significant (p,0.05) main or interaction
effects were found. All other experiments used t tests or one-way
ANOVA followed by Bonferroni post-hoc if the main effect was
significant at p,0.05. Statistical analyses were conducted using
GraphPad Prism (4.0) (GraphPad, San Diego, CA) or SPSS
(Version 11.0, SPSS, Chicago, IL).
Results
CRF-Induced Anxiety-Like Behavior Is Mediated by the
Dynorphin/KOR System
The elevated-plus maze (EPM) was used to measure exploratory
behaviors under dimly illuminated, less stressful conditions that
produced nearly equal times in the open and closed arms to best
reveal anxiogenic effects of treatment. Mice receiving 1 mg CRF
(i.c.v.) spent significantly less time in the open arms of the EPM
compared to saline-injected controls (Fig. 1A). Surprisingly, the
CRF-induced decrease in open arm time was blocked by
pretreatment with the KOR-selective antagonist norbinaltorphi-
mine (norBNI) (10 mg/kg, i.p.) (n=7–8; two-way ANOVA; main
effect of CRF, F(1,24)=6.323, p,0.05; interaction of CRF and
pretreatment, F(1,24)=7.897 p,0.05; Bonferroni post hoc CRF vs.
CRF + norBNI). These results indicate that the anxiogenic-like
effects of CRF require activation of the dynorphin/KOR system.
Pdyn (2/2) mice lacking a functional prodynorphin gene [31]
injected with saline behaved identically to wildtype, littermate Pdyn
(+/+) mice in the EPM, suggesting that dynorphin does not
control the basal anxiety state in the absence of stress (Fig. 1B). In
contrast, CRF did not significantly affect open arm time in Pdyn
(2/2) mice (n=4–8, two-way ANOVA; main effect of genotype,
F(1,20)=8.47, p,0.01; interaction RF and genotype, F(1,20)=4.83,
p,0.05; Bonferroni post hoc CRF Pdyn 2/2 vs. CRF PDyn +/+).
Interestingly Pdyn (2/2) mice spent significantly more time in the
open arm than the closed arm after CRF treatment (p,0.01,
paired t test, closed arm vs. open arm), implying that in animals
lacking dynorphin, CRF may promote exploratory behavior.
These observations suggest that CRF-induced anxiety-like re-
sponses require dynorphin expression.
Mice injected with the selective KOR-agonist U50,488H
(5 mg/kg, i.p.) spent significantly less time in the open arm than
their matched saline-injected controls (Fig. 1c, n=5–7, one-way
ANOVA, F(2,17)=29.87; p,0.001, Saline vs. U50; Bonferroni
post-hoc), implying that KOR activation was sufficient to produce
anxiety-like behaviors. Similar to cannulated mice (Fig. 1A),
norBNI (10 mg/kg, i.p., 2.5 hrs before assay) treatment in the
absence of CRF or U50,488H administration, did not affect open
Figure 1. CRF-induced anxiety-like behavior is mediated by the
dynorphin/KOR system. A, CRF injection (1 mg, i.c.v., 30 min prior to
assay) produced a significant anxiety-like effect (decrease in % open
arm time) in the elevated plus maze (EPM) compared with saline
injected controls. The effect of CRF was blocked by pretreatment with
the KOR antagonist norBNI (10 g/kg, i.p., 2.5 hrs prior to test) (n=7–8;
two-way ANOVA; main effect of CRF, F(1,24)=6.323, p,0.05; interaction
of CRF and pretreatment, F(1,24)=7.897 p,0.05; ** p,0.01 Bonferroni
post hoc)B, CRF (1 mg, i.c.v., 30 min prior to assay) produced a
significant anxiety-like effect in wildtype littermate control Dyn(+/+)
mice, but had no effect in prodynorphin knockout animals (Dyn 2/2)
(n=4–8 per group, p,0.01 CRF in Dyn +/+ vs Dyn 2/2). CRF also
caused a significant increase in open arm time in Dyn (2/2) animals
(p,0.01, t-test, open arm vs. closed arm time, data not shown) C,
Activation of KOR by the selective KOR agonist U50,488 (U50, 5 mg/kg,
i.p.) was also sufficient to cause significant anxiety-like behavioral
effects, whereas treatment with norBNI alone had no effect on the
percent open arm or closed arm time in the EPM under these
conditions. (n=8, one-way ANOVA, **p,0.01, U50 vs. saline).
doi:10.1371/journal.pone.0008528.g001
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(2/2) in this assay. Together these results demonstrate that basal
dynorphin ’’tone‘‘ is negligible in dim light and that the
anxiogenic-like effects of CRF require activation of the dynor-
phin/kappa opioid system.
We also measured the effect of disruption of the dynorphin/
KOR system under intrinsically stressful, ’’bright light‘‘ conditions
(see methods). Saline-treated mice spent significantly (n=4–6;
p,0.05; t6=2.917) less time in the open arm than their norBNI
pretreated (10 mg/kg, i.p) counterparts. Furthermore, Pdyn (2/2)
knockout mice also showed a significantly greater open arm time
compared to wild type controls (n=5; p,0.05, t7=3.147) (Figure
S1). These data corroborate other reports [22,32] using similar
assay conditions and strongly support a role for dynorphin/KOR
in mediating anxiety-like behaviors.
CRF-Induced Anxiety-Like Behavior Is Mediated by
CRF1-R but Not CRF2-R Activation
Prior studies showed that CRF2-R activation caused dynorphin-
dependent conditioned place aversion (CPA) [1]; however, the
relative contributions of CRF1-R and CRF2-R subtypes in
dynorphin/KOR-dependent anxiety-like behaviors are unknown.
The CRF1-R-selective agonist stressin 1 [33] (0.5 mg, i.c.v.)
significantly decreased percent open arm time in the EPM
(Fig. 2A) (n= 6–8, one-way ANOVA, F(3, 20)=4.658; p,0.05,
Saline vs. Stressin 1). Consistent with the findings described above,
the anxiogenic-like effects of stressin 1 were significantly blocked
by norBNI (Fig. 2A) (p,0.05, Saline vs. Stressin + norBNI), as the
percent open arm time was equal to saline-treated animals.
Additionally, mice injected with the CRF2-R-selective agonist
urocortin III [34] (0.5 mg, i.c.v.) showed no difference from
vehicle-treated controls in percent time spent in the open arm
(Fig. 2A). Using CRF2-R knockout mice [11] (CRF2-R 2/2) and
wildtype (+/+) littermate controls to corroborate these results, we
found that the effects CRF in the EPM were unaffected by deletion
of the CRF2-R gene (Fig. 2B, n= 4–8, two-way ANOVA; main
effect of CRF, F(1, 21)=19.02, p,0.001; no main effect of
genotype, F(1,22)=0.26, p.0.05; Bonferroni post-hoc). Together
these data support the conclusion, that CRF1-R activation
mediates CRF-induced dynorphin/KOR-dependent anxiety-like
behavior.
CRF-Induced Conditioned Place Aversion Is CRF2-R
Dependent
Our prior pharmacological characterization [1] led us to predict
that CRF2-R receptors are required for CRF-induced aversion,
and this current report suggests that CRF-induced anxiety-like
behavior may be mediated by a different CRF1-R dependent
activation of dynorphin/KOR signaling. In order to build on this
concept using a conditioned place aversion paradigm (Fig. 3A)
where mice learn to associate CRF injection with a distinct
environmental context, the aversive effects of CRF injection were
examined in CRF2-R (2/2) mice (Fig. 3B). Wildtype littermate
mice injected with CRF showed a significant place aversion (mean
difference: -129643 sec; 95% CI 2238 to 222). In contrast to
wild type, CRF2-R (2/2) mice showed a significant place
preference (mean difference: +235668 sec; 95% CI 46 to 425),
not aversion (n=5–7, P,0.05, paired t-tests). The basis for the
preference to CRF in CRF2-R (2/2) mice is not clear, but it may
be a consequence of the rewarding effects of dopamine release
caused by CRF activation of CRF1-R expressing neurons in
the ventral tegmental area [5,35]. These data illustrate that
CRF1R and CRF2R activation can initiate distinct dynorphin/
KOR-dependent behaviors with CRF1R selectively initiating
dynorphin-dependent anxiety-like responses and CRF2R initiating
dynorphin-dependent place aversion.
Stress-Induced Anxiety-Like Behavior Is Mediated by
Dynorphin/KOR in the BLA
The anxiogenic-like effects of CRF and stressin 1 suggest that
CRF1-R receptor activation induces dynorphin release in the
basolateral amygdala (BLA), a brain region regarded as necessary
Figure 2. CRF-induced anxiety-like behavior is mediated by
CRF1-R but not CRF2-R activation. A, Administration of stressin 1
(0.5 mg, i.c.v.), a selective CRF1-R agonist, produced significant anxiety-
like behavioral effects. Pretreatment with the KOR antagonist norBNI
(10 mg/kg, i.p., 2.5 hrs prior to test) blocked the stressin1-induced
(Stsn) decrease in percent open arm time (n=6–8, one-way ANOVA,
F(3, 20)=4.658; **p,0.05, Saline vs. Stressin 1). In contrast, the EPM
scores for wildtype mice injected with the CRF2-R selective agonist
urocortin III (Uro3) (0.5 mg, i.c.v.), were not significantly different from
the saline-treated group (n=6–8). B, Consistent with the above results,
CRF administration to CRF2-R (2/2) mice still produced significant
anxiety-like behavior (n= 4–8, two-way ANOVA; main effect of CRF,
F(1, 21)=19.02, p,0.001; no main effect of genotype, F(1,22)=0.26,
p.0.05; Bonferroni post-hoc, ** p,0.01 saline (2/2) vs. CRF (2/2)).
doi:10.1371/journal.pone.0008528.g002
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(KORp) shown to selectively label sites of dynorphin action
[1,29,30], we found that CRF injection significantly increased
KORp-ir in the BLA (Fig. 4A,C) (n= 4, one-way ANOVA,
F(2, 10)=10.66; Bonferoni post-hoc, p,0.05 vs. CRF vs. saline).
Antagonism of CRF1-R with a selective dose of antalarmin (10
mg/kg, i.p.) [1] blocked the CRF-induced increase KORp-ir in
the BLA (Fig. 4A,D) (one way ANOVA, F(2, 10)=10.66, p,0.01
CRF vs. CRF + antalarmin). Furthermore, CRF1-R (2/2) mice
showed no marked CRF-induced increase in KORp-ir (Fig. 4A,
n=2).
To determine the behavioral consequences of CRF-induced
dynorphin release and subsequent KOR activation, we injected
saline or norBNI bilaterally into the BLA (2.5 mg/side) as
described [21,23]. We then measured CRF-induced EPM
behavior and changes in KORp-ir. NorBNI antagonism of
KOR is long-lasting and can persist for 2–3 weeks following a
single injection [24,25]. Control brain sections from mice
stereotaxically injected with saline in the BLA show increased
KORp-ir induced by CRF (i.c.v) (Fig. 4B). In contrast, KORp-ir
was not increased in BLA from mice that had been stereotaxically
injected norBNI in the BLA (Fig. 4B,D). The effects of norBNI
injected in BLA were spatially restricted as shown by the presence
of KORp-ir (80 KORp-ir cells/600 mm
2) in the nearby dorsal
medial hypothalamus (DMH) following BLA norBNI. The DMH
is a ventral structure that also expresses high levels of KOR
(Fig. 4A).
In mice bilaterally injected with saline in BLA and subsequently
CRF-treated had a percent open arm time comparable to other
CRF-injected groups in this study (Fig. 5B). However, the
anxiogenic-like response to CRF was abolished for mice injected
with norBNI in the BLA (Fig. 5B) (n=6–8, F(2, 19)=6.350,
P,0.05, saline vs. norBNI BLA and norBNI VPN vs. norBNI
BLA). In contrast, bilateral injection of norBNI in the ventral
posteromedial thalamic nucleus (VPN), a structure that is
contiguous and just medial to the BLA and also expresses KOR
(Figure S2), had no affect on the CRF-induced decrease in percent
time in the open arm (Fig. 5B). Together, these data suggest a
previously unrecognized connection between BLA-dependent
stress-induced anxiety-like behavior, stimulation of the CRF1-R,
and activation of the dynorphin/KOR system.
In order to examine the whether the effects of CRF in BLA on
KOR-mediated anxiety-like behavior generalize to other environ-
mental stressors, we adapted a published procedure using a single
episode of swim stress [28], then measured EPM behavior in
mice locally injected into the BLA with either saline or norBNI
(2.5 mg/side). Following injection and recovery, mice were
exposed to a single acute swim stress (5 min), placed back in their
home cage for 30 min and then assessed in the EPM. As expected,
swim stress induced a significant decrease in the percent time
in the open arm as compared to saline-injected, non-stressed
control animals (Fig 5C). The anxiety-like response to acute stress
was significantly blocked in mice injected with norBNI in the
BLA (Fig. 5C) (n=5–6, Two-way ANOVA; main effect of stress,
F (1,16)=23.54; main effect of treatment, F (1,16)=5.387), and
norBNI alone had no effect on EPM behavior in the absence of
stress (Fig 5C). These data further strengthen the conclusion that
stress-induces KOR activation in the BLA to mediate acute
anxiety-like behaviors.
Discussion
The principal findings of this study are that stress and CRF-
induce dynorphin/KOR activation in the basolateral amygdala to
increase anxiety-like behavior through CRF1-R activation.
Imaging with phospho-KOR antibody revealed that CRF induces
dynorphin release and KOR activation in the basolateral
amygdala, a brain structure associated with the control of anxiety
responses and negative affective state. Previous studies have
demonstrated that the CRF system is a critical mediator of
depression, drug-seeking, and drug withdrawal behaviors
[4,13,16,37,38]. In addition, several reports have implicated the
CRF system in mediating anxiety-like behaviors [10–12,39]. It has
been also been suggested that CRF1-R-induced anxiety-like
behavior may be a critical factor for the initiation of stress-
induced reinstatement to drug seeking because the animal may act
to re-engage drug seeking as a means to relieve the anxiety and/or
dysphoria associated with stress-induced CRF release. Similarly,
dynorphin/KOR activity has been demonstrated to be prode-
pressant, anxiogenic, and mediate stress-induced reinstatement
[17–20]. There are only a few studies suggesting that CRF-R
activation can directly evoke dynorphin release, and these reports
established the potential for these two systems to interact in vivo
[1,40,41]. This body of prior work, combined with the present
study, reveal a connection between CRF1-R dependent activation
and the BLA dynorphin/KOR system, and suggest that
neurobiological mechanisms for stress-induced anxiety and
reinstatement of drug seeking may be mediated via a common
CRF-induced dynorphin/KOR dependent pathway.
We used the elevated plus maze (EPM) as a means to model
anxiety-like behavior in mice in this study. This assay allows
assessment of the behavioral state of a mouse as it explores a dark,
closed environment as opposed to a dimly lit, open one. We
operationally use the term ‘anxiety’ to describe the increase in
Figure 3. CRF-induced conditioned place aversion is CRF2-R
dependent. A, Schematic of the conditioning procedure used to assay
aversion. B, Conditioned place aversion expressed as the individual
animal pre-test (squares) connected by line to the same animal’s post-
test (circles) times spent in the CRF-paired compartment. Dashed lines
represent the mean times during either the pre-test or post-test for
each group. There was no significant difference between CRF2-R (+/+)
and CRF2-R(2/2) mice in pretest scores. CRF (1 mg, i.c.v.) induced a
significant place aversion in CRF2-R +/+ mice (post-test minus pre-test in
the drug paired side, seconds) of -129643 sec. In contrast, CRF injected
in CRF2-R(2/2) mice induced a significant place preference (p,0.05) of
235668 sec (n=5–7, p,0.05 pre-test minus post-test for both groups).
doi:10.1371/journal.pone.0008528.g003
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actual mood state of the mouse cannot be directly determined.
Nevertheless, the EPM is accepted to have predictive validity for
pharmacological agents that reduce anxiety in humans [26,42]. In
this report we established conditions where the saline treated
animal would spend nearly equal time exploring both open and
closed arms of the maze. We presume that the differences in basal
anxiety state in our paradigm compared with those of others
[11,22,32] can be attributed to how intrinsically stressful the assay
conditions are and to rodent strain differences. In fact, when we
tested our mice under conditions where the ambient light was
much brighter, we saw a decrease in the open arm time as
predicted. Consistent with prior reports [22,32], we also found
that norBNI pretreatment and dynorphin knockout blocked this
effect. It is also noteworthy that differences in results obtained by
different research groups concerning the role of CRF2-R in
anxiety-like behavior has been attributed to genetic background
differences, for example, between mixed 129:C57Bl/6 CRF2-R
knockout animals [11] and as compared to those which were on a
more homogeneous C57Bl/6 background [43]. In our study, all
knockout mice were backcrossed C57Bl/6 background to facilitate
the analysis of the gene effects; however, it is important to
recognize that understanding the contributions of differences gene-
gene interactions resulting from differences in genetic background
and differences in behavioral assay conditions may affect the
outcomes and may potentially reveal new insight about factors
controlling affective state.
Our finding that CRF2-R knockout animals do not develop
CRF-induced conditioned place aversion is consistent with our
prior work showing that anti-sauvagine (ASV-30), the selective
CRF2-R antagonist, blocks CRF-induced place aversion. These
results were surprising given that CRF1-R activation contributes to
the aversion evident during drug withdrawal and during
reinstatement to drug seeking [3,6]. Furthermore, CRF1-R activity
has been demonstrated to be required for the maintenance of
ethanol self-administration and mediate withdrawal in nicotine-
dependent rats [44,45]. The difference may suggest that exposure
to drugs of abuse may shift the stress response from being
principally CRF2-R to CRF1-R mediated. In addition, KOR
activation has also been linked to reinstatement of both drug and
Figure 4. CRF-induces CRF1-R-dependent dynorphin/KOR activation in the BLA. A, CRF (1 mg, i.c.v., 30 min) administration in wildtype mice
increased in phospho-KOR-ir in the BLA (upper row, second panel). Pretreatment of wild type mice with antalarmin (10 mg/kg, i.p., injected 1hr
before CRF) blocked the increased CRF-induced KORp-ir in the BLA (upper row, right panel). Similarly, KORp-ir did not qualitatively increase in CRF1-R
(2/2) mice following CRF challenge (panel 3, top row, n=2). As expected, mice injected with saline (vehicle, i.c.v.) showed low levels of KORp-ir in
the BLA (top left). B, Local infusion of norBNI into the BLA of wildtype animals reduced the CRF-induced KORp-ir in the BLA (far right panel) but had
no effect on CRF-induced KORp-ir the dorsal medial hypothalamus (DMH), a nearby brain structure with comparable levels KORp-ir in the untreated
animal. This control region allowed for a regional confirmation of the sphere of norBNI blockade of KOR in injected animals. As predicted norBNI into
the BLA had no effect on KORp-ir in the DMH. C, Schematic of the area imaged and injected with local norBNI; the right box outlines the region
imaged including the BLA and the left box outlines the dorsal medial hypothalamus (DMH), the closest adjacent brain structure in the same slice
where there is high expression of KOR and KORp-ir was visualized following CRF-injection. D, Quantification (per 600 mm
2) of BLA KORp-ir following
saline or CRF-injection. CRF induced a significant increase in KORp-ir as compared to saline, or antalarmin-treated groups. In animals locally injected
with norBNI into the BLA, CRF-induced KORp-ir cell staining was not significantly different than saline treated mice. (*p,0.05, CRF vs. saline,
{{ p,0.01 CRF vs. CRF + antalarmin). Data are from 2–4 independent experiments.
doi:10.1371/journal.pone.0008528.g004
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elevated plus maze measures an acute behavioral response,
whereas the conditioned place aversion assay probes associative
learning with contextual cues. These two behavioral measures are
also likely to explain the divergence in the CRF receptor subtype
contributing to each dynorphin/KOR-mediated response.
We found that the KORp-ir increased in BLA following CRF
injection. Prior work demonstrated that phosphorylation of KOR
is mediated by G-protein coupled receptor kinase 3 following
receptor activation by the endogenous agonist dynorphin [30].
The BLA is a critical brain structure required for stress, fear and
anxiety-like behaviors [36,46]. In addition, CRF1-R has been
shown to be expressed in high density within the BLA [47,48].
Additionally, CRF1-R induces excitatory activity in the BLA and
has been demonstrated to be required for the modulation neuronal
excitatory potentials in BLA [49]. Together with anatomical and
behavioral results revealing a role for CRF1-R activity in the BLA,
a role for these neurons is implicated in modulating anxiety
responses and aversive memories including the modulation of
hedonic state [4,50]. We previously showed that ASV-30 (R2
antagonist) blocked the increase in KORp-ir in the BLA [1], thus
we were surprised to see a lack CRF-induced KORp-ir in the BLA
of CRF1-R (2/2) mice and that the CRF1-R-selective antago-
nism by antalarmin attenuated KORp-ir in the BLA. However, it
is likely that CRF-induced dynorphin release in the BLA
converges to initiate two separate behavioral responses via KOR
activation. In finding that KORp-ir was not increased in CRF1-R
(2/2) animals or in CRF1-R antagonist-pretreated mice following
CRF treatment, combined with a lack of a CRF-induced or stress-
induced increase in the percent open arm time in mice locally
injected with norBNI into the BLA, we infer that stress mobilizes
CRF to induce dynorphin release in BLA via CRF1-R activation.
We were particularly surprised to find that CRF-injection in
CRF2-R knockout mice produced conditioned place preference, as
opposed to solely blocking CRF-induced place aversion. These
data are remarkably consistent with our previous report in
dynorphin knockout animals where CRF-induced place prefer-
ence [1]. The reasons for the apparent rewarding effects of CRF in
CRF2R knockout mice are unknown, but prior studies have shown
that CRF1-R activation can increase dopamine cell firing and
dopamine release in brain structures associated with reward,
including the ventral tegmental area and nucleus accumbens
[5,35]. Similarly, CRF-induced a significant increase in the
time spent in the open arm in pDyn knockout mice, further
corroborating the conceptual framework that in the absence of
dynorphin, mice may be less apprehensive and more likely to
explore the open arm of the elevated plus maze. These results are
in conflict with the lack of place preference to nominally selective
CRF1-R agonists in wildtype mice. Thus, further study of drug
selectivity and possible compensatory change in response to
CRF2-R or pDyn gene deletion is required.
Recent work has suggested that KOR activation can mediate
anxiety-like behavior [22] and that prodynorphin-derived peptides
can regulate basal anxiety behavior [32]. In contrast, other studies
have reported that the dynorphin/KOR system may act to
decrease anxiety-like behavior [51,52]. Additionally, it has been
reported that kappa opioid receptor knockout animals showed
similar percent time spent in open arms to their wild type
counterparts [53]. Studies measuring the effect of KOR-agonists
on acute behavior and reports implicating the utility of KOR
Figure 5. Stress and CRF-induced anxiety is mediated by dynorphin/KOR in the BLA. A, Mice injected with saline (1 ml) into the BLA
showed a decrease in percent open arm time behavior in the EPM following subsequent CRF (i.c.v) injection, whereas bilateral infusion of norBNI
(2.5 mg/side, see methods) in the BLA significantly blocked the CRF-induced (1 mg, i.c.v.) decrease in percent open arm response. Control injection of
norBNI into a nearby brain structure, the ventral posteromedial thalamic nucleus (VPN), had no effect on the CRF-induced anxiety-like behavior
evident in the EPM. (*p,0.05, CRF-injected norBNI/BLA vs. CRF-injected saline/BLA; { p,0.05, CRF-injected norBNI/BLA vs. CRF-injected norBNI/VPN;
n=6–8 per group). B, In further support of a CRF-dependent dynorphin/KOR interaction in the BLA, mice were exposed to a single acute swim stress
(5 min), placed back in their home cage for 30 min and tested in the EPM. As expected, swim stress induced a significant decrease in the percent time
in the open arm as compared to locally injected non-stressed control animals. The anxiogenic-like response to acute stress was significantly blocked
in mice injected with norBNI in the BLA (Fig. 5B) (n=5–6, F(1, 16)=two-way ANOVA; main effect of stress, F (1,16)=23.54; main effect of treatment,
F (1,16)=5.387; p,0.05, Bonferroni post-hoc).
doi:10.1371/journal.pone.0008528.g005
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KOR agonism is thought to be hallucinogenic [54], dysphoric
[1,55], and can induce hypolocomotor activity [53]. The results of
the present study along with others [17,21–23,32] further support
recent efforts to develop and explore KOR antagonists as
therapeutic agents for the treatment of anxiety and depression-
related diseases.
The discovery of CRF was a major milestone, and the
development of CRF receptor antagonists was a big step forward,
but CRF is essential for a healthy response to stress and inhibiting
CRF receptors broadly may block both the adverse effects and the
protective effects of CRF necessary for survival. The converging
effects of stress on the dynorphin kappa opioid system in the BLA
and its key role in mediating the adverse effects of stress implies
that new therapeutic strategies should be directed toward the
development of KOR antagonists.
Supporting Information
Figure S1 Anxiety-like behavior is mediated by the dynorphin/
KOR system. Brightly lit conditions produced a significant
anxiety-like effect (decrease in % open arm time) in the elevated
plus maze (EPM) compared saline controls. This anxiety-like effect
was blocked by pretreatment with the KOR antagonist norBNI
(10 mg/kg, i.p., 2.5 hr prior to test) (n=4–6; p,0.05; t-test,
t6=2.917) Dyn(+/+) wild type littermates showed a significant
anxiety-like response, which was not evident in prodynorphin
knockout animals (Dyn 2/2) (n=5; p,0.05, t-test, t7=3.147).
Found at: doi:10.1371/journal.pone.0008528.s001 (0.56 MB TIF)
Figure S2 The Ventral posteromedial thalamic nucleus (VPN)
expresses Kappa-Opioid receptors. Representative image of U50,
488 challenged (10 mg/kg, i.p., 30 min) BLA brain section stained
with KORp antibody. Data confirms that this thalamic nucleui
expresses KOR.
Found at: doi:10.1371/journal.pone.0008528.s002 (2.74 MB TIF)
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